Bluebird’s stock falls 21% as it says it will focus on U.S. market for gene therapies, citing ‘European payers’

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!

Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.

Your privacy is our priority. Your email address will never be sold or shared with anyone else.